KR20210081353A - 헤테로사이클릭 키나제 억제제 및 이의 용도 - Google Patents

헤테로사이클릭 키나제 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20210081353A
KR20210081353A KR1020217013282A KR20217013282A KR20210081353A KR 20210081353 A KR20210081353 A KR 20210081353A KR 1020217013282 A KR1020217013282 A KR 1020217013282A KR 20217013282 A KR20217013282 A KR 20217013282A KR 20210081353 A KR20210081353 A KR 20210081353A
Authority
KR
South Korea
Prior art keywords
alkyl
group
independently selected
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217013282A
Other languages
English (en)
Korean (ko)
Inventor
피터 세느헨
어월트 세바스찬 메이어
니시트 칸델월
데이비드 밴크로프트
Original Assignee
아이오엠엑스 테라퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이오엠엑스 테라퓨틱스 아게 filed Critical 아이오엠엑스 테라퓨틱스 아게
Publication of KR20210081353A publication Critical patent/KR20210081353A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020217013282A 2018-10-23 2019-10-22 헤테로사이클릭 키나제 억제제 및 이의 용도 Ceased KR20210081353A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18202164.2A EP3643713B1 (en) 2018-10-23 2018-10-23 Heterocyclic kinase inhibitors and uses thereof
EP18202164.2 2018-10-23
PCT/EP2019/078751 WO2020083926A1 (en) 2018-10-23 2019-10-22 Heterocyclic kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20210081353A true KR20210081353A (ko) 2021-07-01

Family

ID=64270595

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013282A Ceased KR20210081353A (ko) 2018-10-23 2019-10-22 헤테로사이클릭 키나제 억제제 및 이의 용도

Country Status (13)

Country Link
US (3) US12172993B2 (https=)
EP (2) EP3643713B1 (https=)
JP (1) JP7667568B2 (https=)
KR (1) KR20210081353A (https=)
CN (1) CN112955447B (https=)
AU (1) AU2019368654C1 (https=)
BR (1) BR112021007643A2 (https=)
CA (1) CA3116674A1 (https=)
DK (1) DK3643713T3 (https=)
IL (1) IL282588A (https=)
MX (1) MX2021004568A (https=)
SG (1) SG11202103142TA (https=)
WO (1) WO2020083926A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
EP3901151B1 (en) * 2020-04-21 2026-04-01 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
CN115398019B (zh) * 2020-08-31 2023-07-07 日本制铁株式会社 钢板及其制造方法
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024539268A (ja) * 2021-10-19 2024-10-28 アイオーエムエックス セラピューティクス アーゲー Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4643861A1 (en) 2024-04-30 2025-11-05 iOmx Therapeutics AG A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
ES2377430T3 (es) * 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012040636A2 (en) * 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
NZ702618A (en) * 2012-06-27 2016-12-23 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
CN106699744B (zh) 2015-11-18 2021-05-11 四川海思科制药有限公司 一种杂环类酰胺衍生物及其制备方法和在药学上的应用
EP3391907B8 (en) * 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
US20230212163A1 (en) 2020-04-21 2023-07-06 Bayer Aktiengesellschaft 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
JP2024539268A (ja) 2021-10-19 2024-10-28 アイオーエムエックス セラピューティクス アーゲー Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順

Also Published As

Publication number Publication date
EP3643713B1 (en) 2025-07-30
DK3643713T3 (da) 2025-11-03
US20210387982A1 (en) 2021-12-16
EP3643713A1 (en) 2020-04-29
WO2020083926A1 (en) 2020-04-30
CN112955447A (zh) 2021-06-11
SG11202103142TA (en) 2021-05-28
AU2019368654A1 (en) 2021-05-06
US20250084076A1 (en) 2025-03-13
EP3870580A1 (en) 2021-09-01
CN112955447B (zh) 2025-09-09
AU2019368654C1 (en) 2025-06-19
CA3116674A1 (en) 2020-04-30
JP2022505645A (ja) 2022-01-14
MX2021004568A (es) 2021-09-08
IL282588A (en) 2021-06-30
BR112021007643A2 (pt) 2021-07-27
US20250101015A1 (en) 2025-03-27
US12172993B2 (en) 2024-12-24
JP7667568B2 (ja) 2025-04-23
AU2019368654B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
US20250084076A1 (en) Heterocyclic kinase inhibitors and uses thereof
CN115667255B (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
US12139480B2 (en) 5-thiazolecarboxamide kinase inhibitor and uses thereof
US20230192701A1 (en) Bicyclic kinase inhibitors and uses thereof
TW202108572A (zh) Ｃｄｋ抑制劑
IL297483A (en) Bifunctional compounds and their uses
US20250282771A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
US20220024944A1 (en) Compounds targeting mutant calreticulin
HK40062784A (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
WO2025059429A1 (en) Modulators of bcl6 for use in a method of treating a cancer or an autoimmune disease
KR20220132538A (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601